Local Fetal Lung Renin-Angiotensin System as a Target to Treat Congenital Diaphragmatic Hernia
- 5 Downloads
Antenatal stimulation of lung growth is a reasonable approach to treat congenital diaphragmatic hernia (CDH), a disease characterized by pulmonary hypoplasia and hypertension. Several evidences from the literature demonstrated a possible involvement of renin-angiotensin system (RAS) during fetal lung development. Thus, the expression pattern of renin, angiotensin-converting enzyme, angiotensinogen, type 1 (AT1) and type 2 (AT2) receptors of angiotensin II (ANGII) was assessed by immunohistochemistry throughout gestation, whereas the function of RAS in the fetal lung was evaluated using fetal rat lung explants. These were morphometrically analyzed and intracellular pathway alterations assessed by Western blot. In nitrofen-induced CDH model, pregnant rats were treated with saline or PD-123319. In pups, lung growth, protein/DNA ratio, radial saccular count, epithelial differentiation and lung maturation, vascular morphometry, right ventricular hypertrophy and overload molecular markers, gasometry and survival time were evaluated. Results demonstrated that all RAS components were constitutively expressed in the lung during gestation and that ANGII had a stimulatory effect on lung branching, mediated by AT1 receptor, through p44/42 and Akt phosphorylation. This stimulatory effect on lung growth was mimicked by AT2-antagonist (PD-123319) treatment. In vivo antenatal PD-123319 treatment increased lung growth, ameliorated indirect parameters of pulmonary hypertension, improved lung function and survival time in nonventilated CDH pups, without maternal or fetal deleterious effects. Therefore, this study demonstrated a local and physiologically active RAS during lung morphogenesis. Moreover, selective inhibition of AT2 receptor is presented as a putative antenatal therapy for CDH.
Congenital diaphragmatic hernia (CDH) is a severe developmental anomaly, with a mean incidence of 1:2,500 live births, in which etiology remains poorly understood (1,2). This congenital anomaly is characterized by a diaphragmatic defect that allows intrathoracic herniation of abdominal organs, and consequently, maldevelopment of the alveoli and pulmonary vessels. For many years, this malformation was thought to be a surgical emergence, solely related to a diaphragmatic defect, and potentially curable by surgical closure of this defect after birth, which allowed lung expansion. However, during 90 years, CDH pathophysiology progressed for a physiological emergence (3,4). It is now clear that lung hypoplasia and consecutive persistent pulmonary hypertension (PH) associated with this disorder are the key determinants of mortality (1, 2, 3, 4). Despite the improvements in understanding CDH pathophysiology and advances in neonatal care, such as the use of extra corporeal membrane oxygenation and inhaled nitric oxide, the mortality (50%) and morbidity rate in CDH newborns remains exceedingly high (1, 2, 3, 4). In humans, CDH can be accurately diagnosed at second trimester during routine ultrasound examination. Therefore it is amenable to antenatal therapies. Hence, antenatal therapies that promote fetal lung growth remain an appealing approach to improve survival of CDH fetuses. However, fetal surgical interventions, such as fetal tracheal occlusion, are invasive, technically demanding, limited by the maternal and fetal risks, and their efficacy is still not determined, with controversial results in survival and morbidity rates (5,6). Therefore, less invasive approaches such as antenatal pharmacological treatment to stimulate lung growth before birth and to treat PH are also under investigation (3,7, 8, 9, 10).
The renin-angiotensin system (RAS) is a classical endocrine system regulating blood pressure, electrolyte and fluid homeostasis, involving several key components, namely angiotensinogen (the hepatic-derived precursor), two critical enzymes, renin (secreted from the juxtaglomerular apparatus of the kidney) and angiotensin-converting enzyme (ACE, pulmonary-bound metalloproteinase), whose sequential actions produce angiotensin I and the physiologically active, angiotensin II (ANGII), respectively (11). ANGII operates on two G proteincoupled receptors, the ANGII type 1 (AT1) and type 2 (AT2) receptors (11). During the last two decades, in addition to this classic endocrine system, evidence has demonstrated the presence of a local RAS with autocrine/paracrine actions in several developing organs, such as fetal kidney, heart, vasculature and adrenal development (12).
Regarding lung morphogenesis, there is some evidence that lung expresses ACE as well as AT1 and AT2 receptors during fetal development (13, 14, 15). However, RAS components expression pattern, as well as effects during lung morphogenesis, is largely unknown.
In this study, we assessed the expression pattern and function of RAS during fetal lung development. Moreover, we assessed the role of RAS as a putative target for treatment of fetal lung hypoplasia in CDH.
Materials and Methods
Animal experiments were performed according to the Portuguese law for animal welfare (16; Diário da República, Portaria 1005/92). Animals were housed in an accredited mouse house and treated as specified by the recommendations of the Helsinki convention (17) and the Guide for the Care and Use of Laboratory Animals, published by the National Academy Press (18).
Experimental Design and Animal Model
In vitro studies were carried out to assess expression and function of RAS in fetal lung, whereas in vivo studies were performed to explore RAS as a target to treat fetal lung hypoplasia using the nitrofen-induced CDH rat model (19).
Sprague Dawley female rats (225 g; Charles River; Barcelona, Spain) were maintained in appropriate cages under controlled conditions and fed with commercial solid food. The rats were mated and checked daily for vaginal plug. The day of plugging was defined as gestational d 0.5 for time-dating purposes. According to the nitrofen-induced CDH rat model (19), at 9.5 d postconception (dpc), randomly selected pregnant rats were exposed to 100 mg nitrofen (2,4-dichlorophenyl-p-nitrophenylether). At different time points, fetuses were harvested by cesarean section. After fetal decapitation, a toraco-laparotomy was performed under a binocular surgical microscope (Leica, Wild M651.MSD, Heerbrugg, Switzerland) to inspect the diaphragm and harvest the organs. Fetuses were assigned to three experimental groups: (i) Control group (C), fetuses not exposed to nitrofen; (ii) Nitrofen group (N), fetuses exposed to nitrofen without CDH; (iii) CDH group, fetuses exposed to nitrofen with CDH.
In Vitro Studies
Normal fetuses removed by cesarean section at 13.5, 15.5, 17.5, 19.5 and 21.5 dpc were killed by decapitation, and lungs dissected and processed for immunohistochemistry (IHC). Lungs of fetuses with 13.5 dpc were also dissected to perform fetal lung explants cultures and posterior western blot analysis.
IHC was performed on formalin-fixed and paraffin-embedded lungs, as previously described by Nogueira-Silva et al. (7). Renin antibody (sc-27320; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used in a 1:25 dilution, ACE antibody (sc-20791; Santa Cruz Biotechnology Inc.) in a 1:75 dilution, angiotensinogen antibody (Abbiotec LLC, San Diego, CA, USA) in a 1:100 dilution, AT1 receptor antibody (sc-1173; Santa Cruz Biotechnology Inc.) in a 1:50 dilution and AT2 receptor antibody (sc-9040; Santa Cruz Biotechnology Inc.) in a 1:25 dilution. Incubation with the Ultra Vision detection system anti-polyvalent horseradish peroxidase (Lab Vision Corporation, Fremont, CA, USA) or with the goat ImmunoCruz™ Staining System (Santa Cruz Biotechnology Inc.) was carried out according to the manufacturer’s instructions.
Fetal Lung Explant Cultures
Recombinant ANGII (Sigma, St Louis, MO, USA), AT1-antagonist (ZD-7155; Tocris Cookson, Bristol, UK) and AT2-antagonist (PD-123319; kindly supplied by Pfizer, Groton, CT, USA) were added daily to lung explants to achieve increasing concentrations of ANGII (from 10−9 to 10−4 mol/L) or ZD-7155 or PD-123319 at 10−5 mol/L. These doses were selected according to the literature (20,21). This set of experiments created the following groups: control (n = 30), ANGII 10−9 (n = 10), ANGII 10−8 (n = 11), ANGII 10−7 (n = 11), ANGII 10−6 (n = 12), ANGII 10−5 (n = 12), ANGII 10−4 (n = 12), ZD-7155 (n = 12), and PD-123319 (n = 15). Furthermore, explants were treated with ANGII at 10−9 mol/L in the presence of ZD-7155 or PD-123319 at 10−5 mol/L, creating the additional groups: ANG 10−9 + ZD-7155 (n = 12) and ANG 10−9 + PD-123319 (n = 15). Cultures were photographed daily and branching morphogenesis was assessed according to Nogueira-Silva et al. (22).
Western Blot Analysis
After 4 d in culture, lung explants treated with ANGII at 10−9 mol/L, ZD-7155 or PD-123319 were processed for western blot analysis of nonphosporylated and phosporylated forms of mitogen-activated protein kinases (MAPKs) [p44/42, p38, JNK (mAbs; Cell Signaling Technology, Danvers, MA, USA)] and phosphatidylinositol-3-kinase (PI3K/Akt) (Cell Signaling Technology) according to Nogueira-Silva et al. (22). For loading control, blots were probed with β-tubulin mAb (Abcam plc, Cambridge, UK) (n = 3). Quantitative analysis was performed with Quantity One 4.6.5 1-D Analysis Software (Bio-Rad Laboratories, Hercules, CA, USA).
In Vivo Studies
Pregnant rats, control or exposed to nitrofen, were anesthetized at 12.5 dpc with a mix of ketamine (75 mg/kg) and medetomidine (0.5 mg/kg) for subcutaneous implantation of an osmotic micropump filled either with saline or PD-123319 (randomly), on mid scapular region (Alzet osmotic pump Model 2ML1; Durect Corporation, Cupertino, CA, USA). Saline or PD-123319 solution was infused with a rate of 10 µL/h (20 mg/kg/d for PD-123319). For the reversal of the sedative effect, atipamezole (0.25 mg/kg) was used and butorfanole (1 mg/kg) was administered immediately after the surgery. Fetuses were assigned to six experimental groups: Control rats treated with saline (C + S); Control rats treated with PD-123319 (C + PD); Nitrofen rats treated with saline (N + S); Nitrofen rats treated with PD-123319 (N + PD); CDH rats treated with saline (CDH + S); and CDH rats treated with PD-123319 (CDH + PD).
Pregnant rats were randomly assigned for cesarean section at 21.5 dpc or for spontaneous delivery at term.
The pregnant rats killed at 21.5 dpc were laparotomized, and after longitudinal hysterotomy, each fetus (C + S, n = 14; C + PD, n = 15; N + S, n = 15; N + PD, n = 12; CDH + S, n = 15; CDH + PD, n = 24) was extracted, weighed and decapitated for organ harvesting (lungs, heart and kidneys). Organs were also weighed independently, organs-to-body weight ratios were assessed and lungs were either snap frozen in liquid nitrogen for biochemical analyses or fixed in 4% paraformaldehyde (PAF) for histological analyses. In this set of experiments, the level of lung hypoplasia was calculated according to Baptista et al. (9).
Irregular or weak breathing
Spontaneous motor activity
Reactivity to stimulus
Lungs, heart and kidneys from all pregnant rats were weighed for maternal organ-to-body weight ratio analysis.
Biochemical Studies for Protein/DNA Ratio Assessment
Total lungs (left and right) were processed to determine protein and DNA contents. Protein content was assessed by Bradford method (24). DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany).
The trachea was cannulated and the lungs were fixed with PAF under a constant pressure of 20 cmH2O. Lungs were embedded in paraffin and sections were used to determine radial saccular count [RSC; using hematoxilin-eosin stain (H&E)], epithelial differentiation [IHC for clara cell secretory protein (CCSP) and prosurfactant protein C (SP-C) and determination of glycogen-content using periodic acid-Schiff stain (PAS)] and medial arterial thickness (using Weigert stain).
RSC was estimated according to Emery and Mithal adapted method (25), at 100× magnification (Olympus BX61 microscope; Olympus, Tokyo, Japan), in 5 animals per group, 6 slides per animal (200 µm apart each other), and 10 segments per slide, by a blinded examiner (E Carvalho-Dias).
Regarding epithelial differentiation, IHC was performed as previously described by Nogueira-Silva et al. (7), briefly described above. CCSP antibody [07-623; Upstate (Millipore), Billerica, MA, USA] was used in a 1:800 dilution and SP-C antibody (AB3428; Chemicon International, Temecula, CA, USA) in a 1:400 dilution. These slides and PAS stained slides were observed and photographed (Olympus BX61 microscope). The percentage of CCSP, SP-C and PAS stained cells per microscopic field was scored in a single-blinded fashion (100× and 400× magnification, respectively) in 6 independent peripheral and 4 central areas per section (6 slides per animal, 200 µm apart each other, and 5 animals per each experimental group). Scoring was as follows: 1, 0–20% cells/field; 2, 20–40% cells/field; 3, 40µ60% cells/field; 4, 60–80% cells/field; 5, 80–100%.
Weigert resorcin fuchsin solution stains elastic fibbers, and it was used for morphometric assessment of pulmonary arteries (26). Pulmonary arteries were distinguished from pulmonary veins on the basis of the structure and position. Arteries that were approximately round [that is, the longest external diameter (ED, distance between the external elastic laminae), did not exceed the minimal ED by more than 50%] and had both clearly visible external and internal elastic laminae were analyzed. As the structural changes and pharmacological effects on pulmonary arteries might be vessel size dependent, we selected for further analysis arteries subcategorized into 3 sizes: ED less than 30 µm, ED 30 µm to 50 µm, and ED greater than 50 µm. Then, using AxionVision Rel. 4.3 (Carl Zeiss, Göttingen, Germany), internal area (IA, defined by internal elastic lamina), external area (EA, defined by external elastic lamina) and total area (TA, defined by edge of the vascular sheath) were measured. The percentage of medial (MA) and adventitial arterial area (AA) were calculated according to the following formulas: MA (%) = [(EA − IA)/EA] × 100; AA (%) = [(TA − EA)/EA] × 100. At least 10 arteries for each section were evaluated, 6 sections per animal (200 µm apart each other), and 3 animals per each experimental group (at 400× magnification).
Right Ventricular Hypertrophy Evaluation
Hearts (C + S, n = 8; CDH + S, n = 6; CDH + PD, n = 8) were used for right ventricle (RV) and left ventricle (LV) dissection (LV contains septum). RV and LV were weighed separately. The ratio RV/LV was determined and used as an index of right ventricular hypertrophy.
Other hearts (C + S, n = 7; CDH + S, n = 6; CDH + PD, n = 6) were dissected, transversally cut and orientated according to short-axis view of the heart, before fixed in PAF and embedded in paraffin. Four micrometer sections were stained with H&E and photographed at 40× magnification (Olympus BX61 microscope). The right ventricular wall thickness was determined in the short-axis view of the heart, in the maximum distance between the right side of the interventricular septum to the right ventricular free wall, using AxionVision Rel. 4.3 (Carl Zeiss) (5 measurements per animal, 20 µm apart each other).
Right ventricular mRNA expression of angiotensinogen, B-type natriuretic peptide (BNP) and endothelin-1 (ET-1), genes previously defined as ventricular overload markers, was evaluated according to Baptista et al. (27).
Data are presented as mean ± SEM. Statistical analysis was performed using the statistical software SigmaStat (version 3.5; Systat Software Inc., Chicago, IL, USA). Multiple group comparisons were made by analysis of variance. For morphometric explants studies, Western blot analysis, biochemical studies, histological studies, right ventricular hypertrophy evaluation and q-PCR studies, one-way ANOVA on ranks was used. Two-way ANOVA on ranks was used for organ-to-body weight ratio analysis and gasometric studies. Student-NewmanKeuls test was used for posttest analysis. Statistical significance was confirmed at P < 0.05.
All supplementary materials are available online at www.molmed.org .
RAS Components Expression Pattern during Fetal Lung Development
Renin was expressed in bronchiolar and also in alveolar epithelium throughout gestation (Figure 1) since 13.5 dpc and appears to be maximal in the most immature buds (see Supplemental Figures 1A–D). Endothelial ACE expression started in larger proximal vessels, early in the gestation, and spreads distally to involve progressively smaller vessels (Figure 1B). Interestingly, ACE protein was also detectable in epithelial cells since 13.5 dpc (see Supplemental Figure 1E). Regarding angiotensinogen, protein expression was clearly observed in epithelial cells since 15.5 dpc (Figure 1C). Mesenchymal tissue also displayed scattered angiotensinogen positive cells, first in endothelial cells and in the later gestational ages (19.5 and 21.5 dpc) clearly in vascular smooth muscle cells (Figure 1C). AT1 receptor protein was first mainly expressed by undifferentiated mesenchyme at 15.5 dpc and, throughout the gestation, it was predominantly expressed by vascular smooth muscle cells and scattered in the mesenchyme (Figure 1D). AT2 receptor was expressed in bronchial epithelial cells and since 19.5 dpc muscle cells of large blood vessels also expressed it (Figure 1E). Moreover, the epithelial AT2 expression was also demonstrated at 13.5 dpc (see Supplemental Figure 1F).
Role of ANGII in Fetal Lung Development
In Vivo Antenatal PD-123319 Treatment Improves Fetal Lung Growth
Biochemical analysis of lung protein and DNA content demonstrated that there was no significant difference in the protein/DNA ratio between C + S, CDH + S and CDH + PD groups (C + S 0.024 ± 0.005; CDH + S 0.030 ± 0.004; CDH + PD 0.026 ± 0.002).
Concerning other organs than lungs, nitrofen treatment (nitrofen and CDH groups) induced decrease of heart-to-body weight (HW/BW) and kidney-to-body weight (KW/BW) ratios. However, antenatal PD-123319 treatment did not significantly change either HW/BW or KW/BW (see Supplemental Figure 2).
Antenatal PD-123319 Treatment Partially Reversed Arterial Structural Abnormality and Decreased Molecular Markers of PH on CDH Model
Right ventricular hypertrophy evaluation 5 min after birth.a
Ratio of right/left ventricular weight
Right ventricular wall thickness (µm)
C + S
0.49 ± 0.08
214.02 ± 9.29
CDH + S
0.44 ± 0.05
200.59 ± 4.27
CDH + PD
0.52 ± 0.05
220.31 ± 12.26
Additionally, expression levels of right ventricular molecular markers of PH (angiotensinogen, BNP and ET-1) were assessed in pups allowed to be delivered at 5 min after birth. In Figure 7D, mRNA levels of these markers normalized to β-actin are shown. CDH + S group presented a significant increase of angiotensinogen and an increase (although not statistical significant) of BNP and ET-1 compared with C + S group. On its turn, PD-123319 treatment significantly decreased these overload markers on CDH pups.
Antenatal PD-123319 Treatment Improves Lung Function and Survival
The adaptation of fetuses to extrauterine life was monitored within the first 5 min after delivery by determining an APGAR-like score (0–8). CDH + S neonates presented an APGAR score of 2.35 ± 0.17, 1.82 ± 0.12 and 2.28 ± 0.18, at 1, 3 and 5 min after birth, respectively. On the other hand, antenatal PD-123319 treatment improved APGAR score to 3.23 ± 0.26, 2.97 ± 0.09 and 2.71 ± 0.13, at 1, 3 and 5 min after birth (P < 0.05), respectively.
Neonatal blood gasometric evaluation 5 min after birth.a
C + S
7.30 ± 0.03
22.69 ± 2.33
102.80 ± 7.78
93.60 ± 2.50
6.83 ± 0.39
N + S
6.94 ± 0.03b
38.49 ± 3.21b
62.50 ± 5.36b
67.25 ± 5.58b
8.50 ± 0.51b
CDH + S
6.92 ± 0.02b
51.05 ± 1.71bc
52.00 ± 6.06b
58.50 ± 7.06b
9.56 ± 0.57b
N + PD
7.18 ± 0.08c
23.62 ± 3.39c
95.67 ± 6.49c
90.83 ± 2.44c
6.88 ± 0.82c
CDH + PD
7.03 ± 0.04de
24.63 ± 5.83d
95.00 ± 8.20d
87.80 ± 3.65d
6.73 ± 0.70d
Regarding potential secondary effects of PD-123319 on maternal organs, their lungs, heart and kidneys were weighed. PD-123319 treatment did not significantly change maternal HW/BW, KW/BW or LW/BW ratios (see Supplemental Figure 3).
This study demonstrated that all components of RAS (renin, ACE, angiotensinogen, AT1 and AT2 receptors) were constitutively expressed in the lung during all studied gestational ages and that ANGII had a stimulatory effect on lung branching, mediated by AT1 receptor, through p44/42 and Akt phosphorylation. This stimulatory effect on lung growth was mimicked by treatment with AT2-antagonist. Therefore, AT2 receptor antagonist was evaluated as a putative antenatal treatment for diseases characterized by fetal lung hypoplasia such as CDH. In an animal model of CDH, antenatal PD-123319 treatment increased neonatal lung growth, ameliorated indirect parameters of PH, improved lung function and survival, without maternal or fetal deleterious effects.
In past years, it has been demonstrated that local ANGII formation and its tissue-specific effects on growth and differentiation are thought to be extremely important for embryonic and fetal development (12). Regarding fetal lung, this study corroborated previous evidences concerning ACE, AT1 and AT2 expression (13, 14, 15,28). For the first time, the present study showed that renin and angiotensinogen are also expressed during lung development. Interestingly, renin, ACE and AT2 were expressed at very early stages (since 13.5 dpc), suggesting an important role for a local RAS since early stages of lung development.
The results of RAS components expression prompted us to hypothesize that a local RAS is active in the developing lung. Therefore, the role of ANGII on lung morphogenesis was evaluated. ANGII supplementation induced an increase in lung explants growth, and it is necessary to stress that this enhancing effect of ANGII on number of peripheral airways buds of lung reached about 37%, whereas the stimulatory effect induced by fibroblast growth factor-10 (FGF-10), a classical and very important lung growth factor, in a similar model of murine lung explants, was around 20% (29). The possible mechanism by which RAS interferes with the airway branching or pulmonary vascular development is still unclear, and further investigation is required. However, it was already substantially demonstrated that reciprocal interactions between airways and blood vessels are critical for normal lung development. For instance, it was demonstrated that ablation of lung epithelium impair lung vascular cells development (30). Moreover, VEGF inhibition in neonatal rats leads to arrested alveolar development, suggesting that inhibition of vascular growth itself may directly impair lung development (31, 32, 33). Thus, given that, in the present study, it was demonstrated that some components of RAS are expressed on epithelium and others on mesenchyme/vascular cells, it is possible that RAS is involved in both processes: airway and vasculature branching.
Interestingly, AT1 receptor inhibitor decreased, whereas AT2-antagonist significantly increased lung growth in explants. This opposite effect of AT1 and AT2 receptors, namely a stimulatory effect of AT1 and inhibitory effect of AT2, is also described on other tissues (34, 35, 36, 37, 38, 39).
Many of the effectors that modulate fetal lung branching seem to activate MAPK and/or PI3K/Akt cascades (40). Thus, MAPK and PI3K/Akt pathway activation by ANGII and AT1 and AT2 antagonists in fetal lung development was investigated. ANGII and AT2 receptor antagonist treatment induced an increase in lung branching by the stimulation of p44/42 and Akt phosphorylation. These intracellular mediators are also involved in AT1 effects on proliferation and survival of cells in other tissues (34,36). Regarding lung growth inhibition induced by AT1 antagonist, it was mediated by a decrease of p-38 and JNK phosphorylation. These MAPK families were already demonstrated to be involved on induction of lung branching (22).
The in vitro studies demonstrated that a local RAS is functional at early stages of lung morphogenesis. Moreover, the significant stimulatory effect on lung growth mediated by AT2 receptor antagonist led us to hypothesize that AT2 could be a new target for treatment of diseases characterized by fetal lung hypoplasia, such as CDH. In fact, AT2 receptor is described to be expressed virtually only during fetal life (11,12,41), which would annul potential maternal adverse effects. Thus, treatment with AT2 antagonist (PD-123319) was selected for the in vivo study, in which the nitrofen-induced CDH rat model (19,42) was used. The gestational age selected for maternal PD-123319 administration was based on the effect observed on lung explants that were harvested at 13.5 dpc.
The nitrofen-induced CDH model is an experimental model of severe lung hypoplasia, which reasonably replicates the major abnormalities and the pathophysiology described in human CDH (42, 43, 44). Although the mechanism by which nitrofen induces the diaphragmatic defect and lung hypoplasia is not fully understood, recent evidences suggest the involvement of abnormalities linked with the retinoid signaling pathway in this model and also in human CDH etiology (42, 43, 44, 45). Indeed, one clinical study demonstrated the presence of decreased levels of retinol and retinol-binding protein in human CDH, suggesting a possible deterioration of retinol transport across the placenta (46). Regarding the nitrofen-induced CDH model, it was already demonstrated that nitrofen inhibits retinal dehydrogenase 2 (RALDH2), a key enzyme responsible for the conversion of retinal to retinoic acid (47). Moreover, the co-administration of retinoids (Vitamin A or retinoic acid) in nitrofen-induced CDH induces lung growth and reduces the incidence of CDH (9,10,48). Interestingly, some studies have described an inhibitory interaction between retinoid acid pathway and RAS, namely in adult cardiac remodeling (49,50). Thus, a possible interaction between retinoid acid pathway and RAS might be present during lung morphogenesis, but the underlying mechanisms remain unclear and further investigation is required.
Maternal PD-123319 subcutaneous administration significantly increased lung growth in control, nitrofen and CDH groups. In fact, in CDH neonates, despite the presence of mechanical forces that compress lungs, PD-123319 induced partial recovery of lung hypoplasia as assessed by LW/BW (an increase of 11.4%). In face of these results and to assess if the treated-lung is structural and functionally ameliorated, we focused further studies in comparing C + S, CDH + S and CDH + PD groups. In human and experimental CDH there is a reduction in peripheral lung development (1,10). PD-123319 treatment stimulated lung growth by promoting distal lung development as measured by the enhanced RSC. The potential clinical relevance of this effect should be emphasized, since such an increase in lung parenchyma can be determinant in providing a better adaptation of CDH fetus to extrauterine life.
Regarding epithelial differentiation and lung maturity, CCSP (a Clara cells marker, marker for proximal lung), SP-C (a type II pneumocytes marker, marker for distal lung) and PAS glycogen stores (a signal of immaturity) were assessed. No differences between groups were detected in CCSP, SP-C and PAS-stained cells score. Contradictory results about lung maturity and surfactant status in CDH animal models have been published, with studies demonstrating that the CDH lung is surfactant deficient (51, 52, 53) and others indicating no change in alveolar surfactant composition, unchanged or even increased surfactant protein expression (54, 55, 56, 57). However, one of the most recent studies performed with human CDH fetuses demonstrated that surfactant maturation is not delayed (54). The present study corroborates the idea that CDH does not appear to interfere or delay epithelial differentiation and surfactant accumulation (54). Moreover, PD-123319 treatment did not impair fetal lung maturation in CDH neonates.
Persistent PH accounts for significant mortality and morbidity in CDH (1,2,58). In severe human CDH and also in nitrofen-induced model of CDH, it was already demonstrated that PH results from decreased number of arteries, increased thickness of media and adventitia of pulmonary arterial walls and distal muscular extension to the non-muscular intraacinar arteries (58,59). In this study, the effect of PD-123319 treatment on PH was indirectly assessed by morphometric pulmonary vascular analysis (59) and its cardiac repercussion by determination of right ventricular hypertrophy index and right ventricle thickness, and quantification of right ventricular overload molecular markers (Angiotensinogen, BNP and ET-1) (27). To better analyze the vessel morphology, areas were measured instead of thickness since this approach avoids the bias introduced by irregular shape of elastic laminae. Thus, PD-123319 treatment induced decrease of MA percentage for all arterial sizes, with maximal effect on smaller arteries. Moreover, CDH + S neonates did not present differences in right ventricular hypertrophy index and right ventricular wall thickness (morphological markers) when compared with C + S group, but they presented an increase of molecular markers of right ventricular overload. Thus, 5 min after birth, CDH + S neonates only presented molecular changes secondary to PH, but not yet morphological alterations (secondary to chronic PH). PD-123319-treated CDH pups presented a significantly decrease of right ventricular overload molecular markers and did not influence morphological markers. Therefore, PD-123319 maternal administration partially reversed pulmonary arterial structural abnormality that characterizes CDH and decreased molecular markers of PH, which suggest that PD-123319 might reduce pulmonary vascular reactivity, and the risk of postnatal persistent PH observed in CDH neonates.
Regarding other antenatal pharmacological strategies to decrease PH in CDH, Luong et al. demonstrated recently that antenatal sildenafil treatment (from 11.5 to 20.5 dpc, daily subcutaneous injection) attenuates PH in experimental CDH (3). In fact, that study demonstrated that antenatal sildenafil treatment improved lung structure, increased pulmonary vessel density and reduced right ventricular hypertrophy in CDH (3). However, in opposition to PD-123319 treatment, sildenafil had not promoted lung growth, as demonstrated by LW/BW, and consequently it did not induce a recover of lung hypoplasia (3). Moreover, it is necessary to stress that the idea that there is PH in CDH, since fetal period, is underlying to Luong’s study (3). Nonetheless, it was already demonstrated that there is vascular hypoplasia in nitrofen-induced CDH and neonatal PH, but it is not yet proven the presence of PH in CDH fetus (27,58,59). Indeed, immediately after the birth, Luong et al. demonstrated the presence of right ventricular hypertrophy (an indirect signal of PH) in CDH neonates (3). In the present study, CDH neonates at 5 min after the birth did not present increase of right ventricular hypertrophy index or right ventricle thickness. However, CDH + S neonates presented an increase of right ventricular overload markers which reveals a molecular cardiac repercussion. According to the literature, it was already demonstrated that CDH vascular pulmonary alterations only affect neonatal and not fetal hemodynamics. Baptista et al. demonstrated that CDH is associated with significant molecular alterations secondary to PH, but only in the right ventricle and after birth (27). Moreover, also in fetal lamb CDH model, it was demonstrated that newborn CDH lambs had no differences in right ventricular weight or right ventricular wall thicknesses compared with control lambs (60). Thus, despite the occurrence of pulmonary vascular modifications from early stages of prenatal development, the present study also shows that PH is only present after birth, likely occurring secondary to vascular hypoplasia that characterizes CDH, and also consequently to pulmonary vasoconstriction, which is secondary to alveolar hypoplasia, hypoxia and acidosis.
So, antenatal PD-123319 treatment interfered and improved the key determinants of mortality associated with CDH, namely lung hypoplasia and PH. Furthermore, maternal PD-123319 administration improved lung function, namely pulmonary gas exchange, as demonstrated by APGAR score, gasometric and survival evaluation. Regarding gasometry it is necessary to stress that due to low fetal blood volume, all blood possibly collected by decapitation was used for gasometric evaluation. So, gasometry evaluated a mix of arterial and venous blood. Nonetheless, antenatal PD-123319 treatment allowed a statistical significant improvement of acidosis, hypercapnia, hypoxia and lactate concentration that characterizes CDH fetuses. The results of these direct indicators of ventilation/perfusion matching quality suggest an obvious improvement of pulmonary gas exchange and peripheral O2 delivery. Furthermore, this enhancement on lung function had important consequences on neonatal survival, namely PD-123319 treatment induced significantly longer average survival time. However, it is necessary to stress that the survival evaluation was performed without neonatal care or ventilatory support. This fact might be the explanation for the death of all neonates, despite the increase on lung function and survival time induced by antenatal PD-123319 treatment.
Regarding potential fetal adverse effects, the nitrofen-exposed pups presented decrease of HW/BW and KW/BW ratios as previously documented (10,61, 62, 63). On the other hand, PD-123319 beneficial effect seemed lung-specific, since HW/BW and KW/BW ratios of the pups were not altered. Concerning potential maternal secondary effects induced by PD-123319, no differences on heart, kidneys and lungs were observed. The absence of maternal deleterious effects could be due to the fact of AT2 receptor expression is dramatically decreased after birth, being restricted to a few organs (11,12,41). Indeed, an increase of AT2 receptor expression during adult life has been only observed under pathological conditions (41).
In conclusion, this study demonstrated the existence of a functional local RAS in fetal lung. Moreover, it establishes AT2 receptor antagonist (PD-123319) as a putative antenatal therapy for pathologies characterized by fetal lung hypoplasia, such as CDH.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
This project was funded by Fundação para a Ciência e a Tecnologia (PTDC/SAU-OBD/108051/2008) and by Secção de Neonatologia da Sociedade Portuguesa de Pediatria (Grant ZERU 2008). P Piairo was supported by Fundação para a Ciência e a Tecnologia (reference SFRH/BD/33410/2008). RS Moura was supported by Fundação para a Ciência e a Tecnologia (reference SFRH/BPD/15408/2005). PD-123319 was kindly supplied by Medical Division of Pfizer Inc, Groton, Connecticut, USA.
We would like to thank to Luís Martins for histological technical support and help on animal euthanasia and to Nuno M Pires for Weigert staining and vascular morphometric analysis support.
- 6.Jani JC, et al. (2009) Severe diaphragmatic hernia treated by fetal endoscopic tracheal occlusion. Ultrasound Obstet. Gynecol. 34:304–10.Google Scholar
- 16.Diário da Repüblica [DR]. (1992) DR 245/92 SÉRIE I-B, Portaria n.° 1005/92 [of 1992 Oct 23]. [cited 2012 Mar 8]. Available from: https://doi.org/www.dre.pt/cgi/dr1s.exe?t=dr&cap=1-1200&doc=19923430%20&v02=&v01=2&v03=1900-01-01&v04=3000-12-21&v05=&v06=&v07=&v08=&v09=&v10=&v11=Portaria&v12=&v13=&v14=&v15=&sort=0&submit=Pesquisar
- 17.World Medical Association [WMA]. (1964) WMA declaration of Helsinki — ethical principles for medical research involving humans. Last amended 2008 Oct. [cited 2012 Mar 8]. Available from: https://doi.org/www.wma.net/en/30publications/10policies/b3/index.html
- 18.Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press. [cited 2012 Mar 8]. Available from: https://doi.org/www.nap.edu/openbook.php?record_id=5140Google Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)